Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Employee Sues Alexion for Sidelining in Reprisal against Whistleblowing
January 19, 2024
- Daiichi, Mitsubishi Curb MR Vaccine Shipments in Response to Takeda’s Recall
January 19, 2024
- LEO Pharma Poised to Build Presence in Japan as Dermatology Leader: CEO
January 19, 2024
- Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
- Takeda’s Hyqvia Earns US Nod for CIDP Maintenance Therapy
January 18, 2024
- US Patent Office Nixes Seagen Patent in ADC Row: Daiichi Sankyo
January 18, 2024
- Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
January 18, 2024
- Parmodia Tops November GP Rep Promotion List, Dayvigo HP Champion for 4th Month
January 18, 2024
- Resuming Production at Quake-Hit Plant Will Take Some Time: Santen
January 17, 2024
- Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
January 17, 2024
- Taisho Set for Delisting as Early as April after Tender Offer Completed
January 17, 2024
- Taisho’s Nanozora Autoinjector Goes on Sale in Japan
January 17, 2024
- Amgen Files TED Drug Tepezza in Japan
January 17, 2024
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Pfizer’s Ibrance Bags Label Update for Tamoxifen Combo in Breast Cancer
January 16, 2024
- Leqembi’s Anticipated EU Approval Delayed into April-June 2024: Eisai
January 15, 2024
- GSK’s Arexvy Hits Market as Japan’s 1st RSV Vaccine
January 15, 2024
- Ono Poised to Overcome Opdivo Patent Cliff and Go Fully Global under New President
January 12, 2024
- Daiichi Sankyo Healthcare to Launch Calonal OTC, Ayumi to Focus on Rx
January 12, 2024
- Santen Curbs Cosopt Mini Shipments after Quake, Nitto Medic to Re-Supply All Products
January 12, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…